Cheng Liu

Cheng Liu

Auto-generated profile, based on publicly available information

Cheng Liu

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2025 in Cancer Research
Verified
Journal Article
Open access
SLShengde Liu
Shengde Liu
ZZZizhen Zhang
Zizhen Zhang
ZWZhenghang Wang
Zhenghang Wang
CLCheng Liu
Cheng Liu
GLGuanghao Liang
Guanghao Liang
SLShen Lin
Shen Lin
Colorectal cancer remains a major cause of cancer-related morbidity and mortality globally, with 30% to 40% of cases developing metastasis, mainly to the liver. Although immunotherapy has shown promise for colorectal cancer treatment, patients with colorectal cancer liver metastasis (CRLM) experience limited therapeutic benefits, potentially because of an immunosuppressive tumor microenvironment. Thus, an urgent need exists to identify the key players that drive CRLM and potentiate immunotherapeutic resistance. In this study, we established liver metastatic cells through continuous passaging in vivo, allowing the screening of RNA expression profiles related to CRLM. A combination of spatial transcriptomic sequencing and single-cell analysis revealed a substantial upregulation of SPP1 expression and secretion in CRLM. SPP1 induced immunotherapeutic resistance by stimulating CXCL12 production by cancer-associated fibroblasts through activation of β-catenin/HIF1α-related transcription. CXCL12 promoted epithelial–mesenchymal transition of colorectal cancer cells but suppressed CD8+ T-cell infiltration. Treatment with a CXCL12 receptor antagonist or anti-SPP1 antibody markedly activated intratumoral CD8+ T-cell infiltration and enhanced the efficacy of anti–PD-1 antibody treatment. Elevated SPP1 and CXCL12 corresponded to immunotherapy resistance in patients with CRLM. Together, this study highlights the potential of the SPP1/CXCL12 axis as a target and a biomarker for precise cancer immunotherapy in CRLM. The intricate interactions within the tumor microenvironment offer promising avenues for improving therapeutic outcomes in patients with CRLM. Significance: SPP1 orchestrates development of an immunosuppressive tumor microenvironment that supports liver metastasis of colorectal cancer cells, offering insights into potential strategies for improving immunotherapy efficacy in liver metastatic colorectal cancer.

5 July 2024 in Science Advances
Verified
Journal Article
Open access
JMJi Ma
Ji Ma
YGYuqing Gong
Yuqing Gong
XSXiaoran Sun
Xiaoran Sun
CLCheng Liu
Cheng Liu
XLXueying Li
Xueying Li
JZJun Zhan
Jun Zhan
The luminal-to-basal transition in mammary epithelial cells (MECs) is accompanied by changes in epithelial cell lineage plasticity; however, the underlying mechanism remains elusive. Here, we report that deficiency of Frmd3 inhibits mammary gland lineage development and induces stemness of MECs, subsequently leading to the occurrence of triple-negative breast cancer. Loss of Frmd3 in PyMT mice results in a luminal-to-basal transition phenotype. Single-cell RNA sequencing of MECs indicated that knockout of Frmd3 inhibits the Notch signaling pathway. Mechanistically, FERM domain-containing protein 3 (FRMD3) promotes the degradation of Disheveled-2 by disrupting its interaction with deubiquitinase USP9x. FRMD3 also interrupts the interaction of Disheveled-2 with CK1, FOXK1/2, and NICD and decreases Disheveled-2 phosphorylation and nuclear localization, thereby impairing Notch-dependent luminal epithelial lineage plasticity in MECs. A low level of FRMD3 predicts poor outcomes for breast cancer patients. Together, we demonstrated that FRMD3 is a tumor suppressor that functions as an endogenous activator of the Notch signaling pathway, facilitating the basal-to-luminal transformation in MECs.

1 January 2025 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
YWYuxin Wang
Yuxin Wang
TXTong Xie
Tong Xie
SXShuai Xiang
Shuai Xiang
CLCheng Liu
Cheng Liu
SCSiyuan Cheng
Siyuan Cheng
ZPZhi Peng
Zhi Peng
Background: Immune checkpoint inhibitors (ICIs) + chemotherapy became standard her2-GC first line treatment. Objectives: The aim of this study is to investigate whether ICIs + chemo provides benefit for patients with low programmed death-ligand 1 (PD-L1) expression. Design: This study is a systematic review and meta-analysis. Data sources: We searched PubMed, Embase, Web of Science, and Cochrane Library as well as the 2019 to 2024 Annual Meetings of the European Society for Medical Oncology, the American Association for Cancer Research, the American Society of Clinical Oncology (ASCO), and the ASCO Symposium on Gastrointestinal Oncology (ASCO-GI) and the ClinicalTrials.gov database. Methods: This systematic review included phase III randomized controlled trials comparing first-line immunotherapy combined with chemotherapy versus chemotherapy alone in advanced gastric cancer. KMSubtraction was used to estimate survival data for those trials that did not report data for the PD-L1 low-expression population. Results: We included a total of nine randomized clinical trials. In patients with combined positive score (CPS) < 1 and CPS < 5, monoclonal antibody + chemotherapy did not show an improvement in overall survival (OS) or progression-free survival (PFS) (CPS < 1 OS: hazard ratio (HR) = 0.91, 95% CI: 0.77–1.08; PFS: HR = 0.88, 95% CI: 0.73–1.07. CPS < 5 OS: HR = 0.92, 95% CI: 0.79–1.08; PFS: HR = 0.78, 95% CI: 0.53–1.14). However, in trials using dual antibodies, patients with PD-L1 CPS < 5 achieved improvements in PFS (HR = 0.64, 95% CI: 0.52–0.80). In trials using tumor area positivity (TAP) scoring, the subgroup with TAP < 5% did not achieve benefits in OS or PFS from immunotherapy plus chemotherapy (OS: HR = 0.92, 95% CI: 0.75–1.13; PFS: HR = 0.91, 95% CI: 0.74–1.13). Conclusion: Our study results indicate that in the first-line treatment of advanced gastric cancer, monoclonal antibody combined with chemotherapy does not provide a survival benefit compared to chemotherapy alone for patients with low PD-L1 expression. However, it is noteworthy that in the COMPASSION-15 trial, patients with CPS < 5 achieve significant improvements in OS and PFS, which may be related to the bispecific antibodies and needs to be validated by further studies. Trial registration: This study was registered in PROSPERO (CRD42024568972).

2 January 2026
Verified
Other
Open access
SLShengde Liu
Shengde Liu
ZZZizhen Zhang
Zizhen Zhang
ZWZhenghang Wang
Zhenghang Wang
CLCheng Liu
Cheng Liu
GLGuanghao Liang
Guanghao Liang
SLShen Lin
Shen Lin
Colorectal cancer remains a major cause of cancer-related morbidity and mortality globally, with 30% to 40% of cases developing metastasis, mainly to the liver. Although immunotherapy has shown promise for colorectal cancer treatment, patients with colorectal cancer liver metastasis (CRLM) experience limited therapeutic benefits, potentially because of an immunosuppressive tumor microenvironment. Thus, an urgent need exists to identify the key players that drive CRLM and potentiate immunotherapeutic resistance. In this study, we established liver metastatic cells through continuous passaging in vivo, allowing the screening of RNA expression profiles related to CRLM. A combination of spatial transcriptomic sequencing and single-cell analysis revealed a substantial upregulation of SPP1 expression and secretion in CRLM. SPP1 induced immunotherapeutic resistance by stimulating CXCL12 production by cancer-associated fibroblasts through activation of β-catenin/HIF1α-related transcription. CXCL12 promoted epithelial–mesenchymal transition of colorectal cancer cells but suppressed CD8+ T-cell infiltration. Treatment with a CXCL12 receptor antagonist or anti-SPP1 antibody markedly activated intratumoral CD8+ T-cell infiltration and enhanced the efficacy of anti–PD-1 antibody treatment. Elevated SPP1 and CXCL12 corresponded to immunotherapy resistance in patients with CRLM. Together, this study highlights the potential of the SPP1/CXCL12 axis as a target and a biomarker for precise cancer immunotherapy in CRLM. The intricate interactions within the tumor microenvironment offer promising avenues for improving therapeutic outcomes in patients with CRLM.Significance:SPP1 orchestrates development of an immunosuppressive tumor microenvironment that supports liver metastasis of colorectal cancer cells, offering insights into potential strategies for improving immunotherapy efficacy in liver metastatic colorectal cancer.

2 January 2026
Verified
Other
Open access
SLShengde Liu
Shengde Liu
ZZZizhen Zhang
Zizhen Zhang
ZWZhenghang Wang
Zhenghang Wang
CLCheng Liu
Cheng Liu
GLGuanghao Liang
Guanghao Liang
SLShen Lin
Shen Lin
Figure S7 Tumor-derived SPP1 promotes the progression of CRLM and immunotherapy resistance independent of macrophages. A Flowchart of the intrasplenic injection model of liver metastasis in mice using OE-SPP1 or OE-vector MC38 cells. i.s.v., intrasplenic injection; i.p., intraperitoneal injection. Clo: Clodronate-liposomes. B Representative H&E staining of metastatic livers from C57BL/6J mice intrasplenically implanted with SPP1-overexpressing or vector-overexpressing MC38 cells, followed by treatment with anti-PD-1 antibody. Scale bar, 1 mm. C Quantification of liver weight and tumor burden in liver metastases from the indicated mouse groups (n = 5 per group), with tumor burden assessed by the tumor-to-liver area ratio in tissue sections. D Flow cytometric analysis of macrophage populations in liver metastases from the indicated mouse groups (n = 5 per group). Mac+ represents the control group, MacΔ represents the macrophage depletion group. E, F Flow cytometric analysis of IFN-γ+ CD8+ and GZMB+ CD8+ T cell populations in liver metastases from the indicated mouse groups (n = 5 per group). G, H Collagen content was evaluated by Masson’s trichrome staining, α-SMA expression levels were assessed via IHC analysis, and cell apoptosis was measured by TUNEL staining. Integrated Optical Density (IOD) was used for quantification in all assays (n = 5 per group). Scale bar = 40 μm. I Flow cytometry validated the engraftment of hCD45+ cell 7 days post implantation in each group of mice (n = 3/group). All results are presented as mean ± SEM. P values were determined by one-way ANOVA. ns, no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001.

2 January 2026
Verified
Other
Open access
SLShengde Liu
Shengde Liu
ZZZizhen Zhang
Zizhen Zhang
ZWZhenghang Wang
Zhenghang Wang
CLCheng Liu
Cheng Liu
GLGuanghao Liang
Guanghao Liang
SLShen Lin
Shen Lin
Figure S6 Talabostat mesylate reverses the progression of CRLM and synergizes with PD-1 blockade therapy A-C Collagen content assessed by Masson’s trichrome staining, and expression levels of α-SMA and CD8 evaluated by mIHC analysis. D, E Ki-67 and TUNEL staining were performed on PDOX tumor tissues to evaluate cell apoptosis and proliferation. F H&E analysis in tumor tissues from each group. G Flow cytometry validated the engraftment of hCD45+ cells 14 days post implantation in each group of mice (n = 3/group). H Collagen content was assessed using Masson’s trichrome staining, while expression levels of α-SMA and CD8 were evaluated through mIHC analysis. Ki-67 and TUNEL staining were performed on PDX tumor tissues to assess cell apoptosis and proliferation. H&E analysis was conducted on tumor tissues from each group. I, J Collagen content assessed by Masson’s trichrome staining, and expression levels of α-SMA evaluated by IHC analysis. IOD: Integrated Optical Density. K TUNEL staining was performed to evaluate cell apoptosis. All results are presented as mean ± SEM. P values were determined by one-way ANOVA. **P < 0.01, ***P < 0.001.